Edition:
India

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

25.17EUR
18 May 2018
Change (% chg)

€0.02 (+0.08%)
Prev Close
€25.15
Open
€25.26
Day's High
€25.41
Day's Low
€25.12
Volume
663,481
Avg. Vol
643,513
52-wk High
€27.73
52-wk Low
€21.50

Chart for

About

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €15,167.80
Shares Outstanding(Mil.): 687.55
Dividend: 0.14
Yield (%): 1.29

Financials

  GRLS.MC Industry Sector
P/E (TTM): 29.70 30.95 32.75
EPS (TTM): 0.82 -- --
ROI: 5.94 14.84 14.38
ROE: 16.00 16.34 16.07

BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY

* Q1 EBITDA 297.4 MILLION EUROS VERSUS 306.0 MILLION EUROS YEAR AGO

03 May 2018

BRIEF-Grifols Concludes Experimental Phase Of Clinical Trial On Alzheimer

* SAYS CONCLUDES EXPERIMENTAL PHASE OF AMBAR, A CLINICAL TRIAL ON ALZHEIMER'S DISEASE

22 Mar 2018

BRIEF-Grifols To Buy German Pharmaceutical Company Haema For 220 Mln Euros

* SAYS REACHES DEAL WITH ATON GMBH TO BUY 100 PERCENT OF HAEMA AG FOR 220 MILLION EUROS ON A DEBT FREE BASIS ‍​ Source text for Eikon:

20 Mar 2018

Spanish stocks - Factors to watch on Wednesday

The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

14 Mar 2018

BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.

* GRIFOLS - ANNOUNCES NEW AGREEMENT WITH HENRY SCHEIN TO DISTRIBUTE NORMAL SALINE SOLUTION IN THE U.S.

05 Mar 2018

Spanish stocks - Factors to watch on Wednesday

The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

28 Feb 2018

BRIEF-Grifols FY Net Profit Up At 662.7 Mln Euros

* FY NET SALES 4.32 BILLION EUROS VERSUS 4.05 BILLION EUROS YEAR AGO

28 Feb 2018

BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment

* GRIFOLS HYPERRAB® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

06 Feb 2018

BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets

* SEES POSITIVE NON-RECURRING IMPACT OF ABOUT 90 MILLION EUROS NET IN Q4 FROM US TAX REFORM AND REASSESSMENT OF ASSETS RELATED TO ARADIGM Source text for Eikon:

30 Jan 2018

BRIEF-Grifols Buys 51 Pct Of Medkeeper

* SAYS PURCHASE RESULT OF $98 MLN CAPITAL INCREASE IN MEDKEEPER

26 Jan 2018

Earnings vs. Estimates